- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02365389
Once Daily In-situ Forming Versus Twice-daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis (MNZ)
Assiut University Hospital - Women Health Hospital
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bacterial vaginosis (BV) is one of the most frequently diagnosed infections in women attending genitourinary clinics. As 50% of cases of BV are asymptomatic, the true prevalence of this condition in the community is uncertain.Metronidazole (MTZ) is considered the drug of choice for the treatment of BV. It can be given either orally or locally. Formulations for the local administration of the drug include gels and suppositories.
The acceptance of suppositories is lower than the oral administration of the drug as they might cause irritation and thus affecting the patient's compliance. Moreover, the mode of administration of MTZ does not have a significant difference in the eradication of the pathogenic bacteria .
Among the metronidazole gels and lactic acid gels, for local application, lactic acid gels have been found to be more efficient and safer. The recurrence of BV is less common in patients treated with lactic acid gel when compared with patients treated with metronidazole gels. This may be attributed to the inhibition in the growth of the lactobacilli when MTZ is used for the treatment and depends on the concentration of the lactobacilli .
Intravaginal deliveries of MTZ for the treatment of BV have shown that there was an improvement in the clinical symptoms of the patients within 21-30 days of the starting of the treatment. Unfortunately, the vagina was not recolonized with lactobacilli within the stated period . The use of formulation consisting policarbophil-carbopol and lactic acid-chitosan mucoadhesive vaginal gels has also been reported and both of them have been found to be safe .
Cure rates following intravaginal treatment with MTZ account for 80-90% at the end of treatment and one month after the end of therapy. However, three months after the end of therapy the rate of relapses can overcome 30%. Persistence of an adherent bacterial biofilm, containing mostly Gardenerlla vaginalis is the main reason for failure of BV treatment .
Suppressive treatment with MTZ gel has been investigated with variable results . Moreover, long-term treatment with MTZ is not recommended because of the high incidence of gastrointestinal adverse reactions, the risk of peripheral neuropathy, and Candida super infection.
Although the patients are known to tolerate gels better than suppositories or ointments, the direct application of gels into the diseased sites of vagina might be difficult as well as improper. Therefore, vaginal therapy would be significantly improved if an intravaginally administered drug can retain at the site of administration for prolonged time .
The in situ forming hydrogel is a stimuli sensitive hydrogel that exists as an aqueous solution before administration. When exposed to external physical stimuli like heat, it undergoes reversible volume-phase transition, then immediately turned into standing gels after its contact with the mucosa .Recently, in situ gel drug delivery system has been investigated as a more convenient dosage form of topical applications. It's easy to be applied into the vagina with accurate dosing of liquid before turning to gel with even spreading. It had been tried before and proved effectiveness, safety and tolerance .
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with proven diagnosis of bacterial vaginosis infection from the Outpatient Gynecological Clinic in Women Health Center Assiut University.
Exclusion Criteria:
- Women refusal to participate in the study.
- Pregnant and nursing Women.
- Anticipation of difficulty of subsequent communication with the woman.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A received in situ MTZ vaginal gel
Received in situ MTZ vaginal gel once daily for 5 days.
Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride).
Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
|
MTZ vaginal gel once daily for 5 days
|
Active Comparator: Group B received conventional MTZ vaginal gel
Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
|
Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical improvement of vaginitis.
Time Frame: 6 months
|
Therapeutic success will be defined as the presence of at least 3 signs of Amsel's criteria (Milky, homogeneous, adherent discharge; vaginal pH > 4.5; release of fishy amine odor from vaginal fluid when mixed with 10% KOH (whiff test); and presence of > 20 of clue cells).
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Vaginal gell
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginitis
-
Amneal Pharmaceuticals, LLCCompletedAtrophic Vaginitis Due to MenopauseUnited States
-
Fayoum UniversityRecruitingAtrophic Vaginitis | Postmenopausal Atrophic VaginitisEgypt
-
Ain Shams UniversityNetherlands: Ministry of Health, Welfare and SportsUnknown
-
Tulane University Health Sciences CenterCompletedVaginitis Trichomonal or Due to TrichomonasUnited States
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Diseases | Atrophic VaginitisBrazil
-
Assiut UniversityUnknownTrichomonas Vaginalis Genotyping in Upper Egypt | Vaginitis Trichomonal
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Disease | Atrophic VaginitisBrazil
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal AtrophyUnited States, Canada
-
Novo Nordisk A/SCompletedMenopause | Postmenopausal Vaginal AtrophyGermany
-
University of Alabama at BirminghamCompletedVaginal Atrophy | Female Urogenital Diseases | Postmenopausal Symptoms | Postmenopausal Atrophic Vaginitis | Genitourinary DiseaseUnited States
Clinical Trials on MTZ vaginal gel
-
University of Campinas, BrazilFaculty Sao Leopoldo Mandic CampinasCompletedChronic PeriodontitisBrazil
-
Università degli Studi dell'InsubriaUnknown
-
BioClin BVAvaniaRecruiting
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHPV Infection | Lesion CervixSpain
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Procare Health Iberia S.L.Adknoma Health ResearchActive, not recruitingHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Sarawak General HospitalNot yet recruitingSexual Dysfunction | Atrophic Vaginitis | Menopause Related Conditions | Genitourinary Syndrome of Menopause
-
BiosynUnited States Agency for International Development (USAID); FHI 360Unknown
-
BiosynUnited States Agency for International Development (USAID); FHI 360Unknown
-
Tulane University Health Sciences CenterCompletedVaginitis Trichomonal or Due to TrichomonasUnited States